Abstract: 40 cas de maladie de Behcet ont ete etudies entre 1977 et 1985. Il s'agissait 1 hommes (62 %) et de 129 femmes (38 %). La moyenne d'age est de 25.5 ecart type de 9.1. 334 cas avaient des Iesions muqueuses (98 %). L'aphtose de etait presente dans 333 cas (97 %), I'aphtose genitale dans 245 cas (72%). ~f~es-avatent des lesions cutanees (74 %). Les pseudo-folliculites etaient !ntes dans 257 ...
Abstract: The skin hyper reactivity (SHR) as detected by the pathergy test is a common feature of Behcet's Disease (BD) in Middle East Countries and in Japan, but not in Western Countries. Yazici et al showed it's sensitivity and it's specificity. As the SHR in pathergy test is revealed by a pseudo folliculitis, it may have the same significance as the spontaneous pseudo folliculitis (PF) of BD. Thus if a patient ...
Abstract: In 225 patients with definit Behcet's Disease I5 clinical and 5 paraclinical parameters (CBC,ESR, urinalysis,B5,Pathergy test) were statistically analyzed. The chi-square test (X2) was used for the analysis of difference and P values smaller than 0.05 were accepted as a significative difference between male and female patients. Ophthalmologic manifestations were more frequent in males (80%) than females (63%),X2=7.91,0.01> P> 0.001.The difference concern specially the uveitis (73% males,55% females,X2=7.65,0.01>P>0.001). In osteoarticular ...
Abstract: In this case study 100 patients with confirmed Behcet's disease have been in reviewed. The following manifestations were observed: buccal aphthous ulcerations 98 per cent, genital ulcerations 63 per cent, positive Behcetine test in 81 per cent, ocular involvement 80 per cent, positive HLA-B5 74 per cent, skin lesions 68 per cent, articular manifestations 63 per cent, digestive problems 21 per cent, thrombophlabitis of the extremities 17 per cent, neurologic ...
Abstract: 35 patients with the “complet form“ of Behcet’s disease, according to the criteria of Behcet’s Disease Research Committee of Japan were selected for study. The choice of complet forms make possible to have a more homogenous group of patients to evaluate the effect of levamisole on the major symptoms of the disease. The patients were treated with levamisole at least for 3 to 6 months, they had no cytotoxic ...